Urinary Concentrations of Benzophenone-Type Ultra Violet Light Filters and Semen Quality

Germaine M. Buck Louis, PhD[a], **Zhen Chen, PhD**[b], **Sungduk Kim, PhD**[b], **Katherine J. Sapra, MPH, MPhil**[a], **Jisuk Bae, MD, PhD**[a,c], and **Kurunthachalam Kannan, PhD**[d,e]

[a]Office of the Director, Division of Intramural Population Health, *Eunice Kennedy Shriver* National Institute of Child Health & Human Development, Rockville, Maryland 20852, USA

[b]Biostatistics and Bioinformatics Branch, Division of Intramural Population Health, *Eunice Kennedy Shriver* National Institute of Child Health & Human Development, Rockville, Maryland 20852, USA

[c]Department of Preventive Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 705-718

[d]Wadsworth Center, New York State Department of Health, Albany, New York, USA

[e]Department of Environmental Health Sciences, School of Public Health, The University at Albany-SUNY, Albany, New York, USA

Abstract

Objective—To assess benzophenone-type ultra violet (UV) filter concentrations, chemicals used in sunscreen and personal care products, and semen endpoints.

Design—Cohort.

Setting—16 counties in Michigan and Texas

Participants—413 men provided semen and urine samples, 2005–2009. Five UV filters were quantified (ng/mL) in urine using liquid chromatography-triple-quadrupole mass spectrometry: BP-1 (2,4-dihydroxybenzophenone), BP-2 (2,2′,4,4′-tetrahydroxybenzophenone), BP-3 (2-hydroxy-4-methoxybenzophenone), BP-8 (2,2′-dihydroxy-4-methoxybenzophenone), and 4-OH-BP (4-hydroxybenzophenone). Using linear regression, beta coefficients (β) and 95% confidence intervals (CIs) for each chemical dichotomized at the 75th percentile and Box-Cox transformed semen endpoint were estimated, after adjusting for age, BMI, cotinine, season, and site.

Interventions—None.

Main Outcome Measures—35 semen endpoints.

Corresponding author: Germaine M. Buck Louis at above address, 301-496-6155, 301-402-2084 (fax), louisg@mail.nih.gov.

Results—BP-2 was associated with diminished sperm concentration (β=−0.74; 95% CI −1.41, −0.08), straight (β=−4.57; 95% CI −8.95, −0.18) and linear movement (β=−3.15; 95% CI −6.01, −0.30), more immature (β=0.38; 95% CI 0.15, 0.62) sperm, and a decreased percentage of other tail abnormalities (β=−0.16; 95% CI −0.31, −0.01). BP-8 was associated with decreased hypo-osmotic swelling (β=−2.57; 95% CI −4.86, −0.29) and higher acrosome area (β=1.14; 95% CI 0.01, 2.26). No associations were observed for BP-1, BP-3 or 4OH-BP.

Conclusion—The findings suggest that specific UV filters may be associated with some aspects of semen endpoints, but await future corroboration.

Keywords

benzophenones; fecundity; semen; sperm; sunscreens

Introduction

Various classes of persistent environmental chemicals or those that resist degradation and bioaccumulate and biomagnify within food chains, such as dichlorodiphenyldichloroethylene (*p,p′*-DDE), perfluorinated alkyl acids (PFAAs) or polychlorinated biphenyls (PCBs), have been associated with changes in semen quality in some study populations suggesting possible implications for male fecundity (1–3). Interest in non-persistent chemicals, or those compounds with short half-lives ranging from hours to days, is growing in light of their ubiquitous sources of exposure for contemporary populations and reported association with semen quality. For example, both bisphenol A (BPA) and phthalates, or chemicals used in the manufacture of polycarbonate plastics and to enhance the flexibility of plastics among other uses, respectively, have been associated with diminished semen quality in some (4, 5) but not all (6, 7) study populations.

Recently, concern has arisen about benzophenone (BP)-type ultra violet (UV) light filters, given the detection of one such compound in 97% of the U.S. population during 2003–2004 (8), and a comparable percentage in Chinese adults and children during 2010–2012 (9). With increasing recognition of the harmful human health effects attributed to UV radiation, BP-type UV filters have been added to personal care products, insect repellents and sunscreens to block or minimize the harmful effects of UV light on human skin and hair. These chemicals are also used to coat surfaces exposed to sunlight, including some food packaging (10) where they can migrate to food (11).

Humans are exposed to BP-type UV filters largely through dermal absorption, with evidence that re-application of certain products may further increase systematic absorption (12, 13).

BP-type UV filters represent approximately 29 compounds, though the sources for some are unknown and not all are in commercial use. In recent years, a few BP-type UV filters have been reported to have various hormonal activities, including *in vitro* and *in vivo* estrogenic, anti-estrogenic and anti-androgenic effects (14–16). For example, the UV filter BP-2 (2,2′, 4,4′-tetrahydroxybenzophenone) has been shown to be capable of binding to estrogen receptors and exerting estrogen-agonistic activity (16). Only minimal research has focused on human health endpoints. A recent paper reported that BP-1 (2,4-

dihydroxybenzophenone) was associated with endometriosis, an estrogen dependent gynecologic disease (17). Also, urinary concentration of specific BP-type UV filters in men were associated with diminished couple fecundity manifesting in a longer time required to achieve pregnancy (18). In light of these emerging data, we explored the relation between five BP-type UV filters and semen quality among men recruited from the general population who were not seeking clinical care.

Materials and Methods

Study Population

Male partners of couples participating in the Longitudinal Investigation of Fertility and the Environment (LIFE) Study comprised the study population for this work. Briefly, 501 couples discontinuing contraception and trying for pregnancy were recruited from 16 counties in Michigan and Texas between 2005–2009 (19). Eligibility criteria for participation included: 18 years of age, in a committed relationship, no history of clinical diagnosis of infertility, and an ability to communicate in English or Spanish.

Data Collection

Upon enrollment into the cohort, male partners completed baseline interviews followed by a standardized anthropometric assessment to determine body mass index (BMI; weight in kg/height in m^2). Men provided urine and blood specimens for the quantification of urinary UV-filters and serum cotinine, respectively. In addition, 473 (94%) men provided a semen sample of which 378 (80%) provided a second sample approximately one month later using specifically designed at home collection kits. Semen samples were mailed over-night to a centralized andrology laboratory where analyses were performed within 24 hours. Among the 501 participating men, 413 had provided semen samples and had sufficient urine available for the quantification of BP-filters and comprise the study population for this work. Human subjects' approval was obtained from all collaborating institutions, and all men provided informed consent before any data collection.

Toxicologic Analysis

Five UV filters were quantified: BP-1, BP-2, BP-3 (2-hydroxy-4-methoxybenzophenone), BP-8 (2,2′-dihydroxy-4-methoxybenzophenone), and 4-OH-BP (4-hydroxybenzophenone). Of note, BP-3 is metabolized by phase I and II reactions, resulting in its conjugation and urinary excretion (8, 20). BP-1, BP-2, BP-8, and 4OH-BP are metabolic derivatives of BP-3, as generated in phase I and II reactions (21, 22). As such, urine is an appropriate matrix for quantifying these chemicals.

Urinary quantification of the 5 UV-filters were determined using established standard operating procedures (21, 23), and performed using isotopic dilution high performance liquid chromatography-triple quadrupole tandem mass spectrometry with recoveries ranging from 95–107%. All laboratory analyses included ongoing quality assurance and quality control procedures inclusive of procedural blanks. The limits of detection (LOD) for the five UV filters in urine ranged from 0.01 to 0.02 ng/ml. All machine-measured concentrations were reported without substituting for concentrations below the LOD to avoid introducing

bias associated with this practice (24, 25). Concentrations of UV filters are presented as ng/ml of urine or μg/g creatinine. Urinary creatinine was quantified (mg/dL) in 0.15 ml of urine using the Roche/Hitachi Model 912 clinical analyzer (Dallas, TX) and the Creatinine Plus Assay. Serum cotinine concentration was quantified (ng/ml) in 1 ml of serum using liquid chromatography-isotope dilution tandem mass spectrometry (26).

Semen Collection and Analysis

Males collected up to two semen samples approximately a month apart using an established at home collection protocol (27). Briefly, men were asked to abstain from intercourse for two days and to collect the sample by masturbation without the use of any lubricants. A glass collection jar was provided for collection to which a temperature data logger (I-Button, Maxim Integrated, Jan Jose, CA) was attached to record temperature during the 24-hour interval from collection to laboratory analysis. Men were asked to place a specifically prepared sperm migration straw filled with hyaluronic acid and plugged at one end (Vitrotubes #3520, VitroCom Inc., Mt. Lakes, NJ) into the ejaculate after collection to capture sperm motility at the time the specimen was collected. Men recorded the last day of ejaculation and any spillage on the container's label. Semen samples were shipped overnight allowing for analysis within 24-hours by established andrology laboratories.

Semen samples were quantified for 35 semen endpoints: 5 general characteristics (volume, straw distance, sperm concentration, total sperm count, hypo-osmotic swollen), 8 motility measures, 8 morphology measures, 12 morphometry measures, and 2 sperm chromatin stability assay (SCSA®) measures. Sperm motility was quantified using the HTM-IVOS (Hamilton Thorne, Beverly, MA) computer assisted semen analysis system (CASA), while sperm viability was measured using the hypo-osmotic swelling (HOS) assay and sperm concentration using the IVOS system and the IDENT™ stain. Sperm morphometry was performed using the IVOS METRIX system. The SCSA® was used according to the methods of Evenson (28) to quantify DNA fragmentation and the percent of high stainable sperm. The distance traveled by the vanguard sperm in the migration straw was measured to the nearest mm. The above semen endpoints were measured by a single andrology laboratory at the National Institute for Occupational Safety and Health. Sperm morphology was performed by Fertility Solutions®, Inc. (Cleveland, OH) using both the traditional and strict morphology techniques (29, 30). Ongoing quality assurance and quality control procedures were in place throughout analysis, inclusive of the use of Westgard Rules and monitoring for drift. All data were inspected to ensure the absence of batch related differences and/or laboratory drift. None were detected. Analysis of the second semen sample was restricted to general characteristics, motility and sperm head measurements, largely for budgetary reasons and to verify azoospermia in the first sample. Distributions for all semen quality endpoints have been previously published (27).

Statistical Analysis

We assessed the completeness of data and used Chi-square and nonparametric Wilcoxon tests to assess differences in categorical and continuous socio-demographic characteristics, respectively, with regard to BP-filter concentrations. The distributional properties of all

chemicals and semen endpoints were assessed. Specific semen endpoints were transformed using Box-Cox procedures and the Shapiro-Wilk W statistics (31).

Specifically, we observed that 14 endpoints (i.e., swollen, average path velocity, straight line velocity, curvilinear velocity, amplitude head displacement, beat cross frequency, straightness, linearity, area, width, perimeter, elongation factor, acrosome area of head, and traditional normal) required no transformation, 14 required natural logarithm transformation (i.e., length, straw distance, round, pyriform, bicephalic, taper, megalo head, micro head, neck or mid-piece abnormalities, coiled tail, other tail abnormalities, immature sperm, DNA fragmentation index, and high DNA stainability) and 7 required cubic root transformation (i.e., volume, total count, sperm concentration, percent motility, strict criteria, amorphous, and cytoplasmic droplet). Detailed information on the varying transformation procedures is published elsewhere (32).

We used linear mixed models with fixed and random effects to assess changes in semen endpoints associated with BP-type UV filters. Specifically, we estimated the change (beta (β) coefficients and accompanying 95% confidence intervals (CIs)) in semen endpoints for men above the 75th percentile for each chemical concentration relative to men below. We selected this dichotomy to differentiate men who were more highly exposed from less exposed men, and in light of few data to help inform the modeling of chemical distributions relative to semen quality. A random intercept was used in the mixed models to account for the correlation arising from the use of two semen samples for outcomes measured in both samples (i.e., volume, sperm concentration, total sperm count, hypo-osmotic swollen, next-day motility, and sperm head morphology). Regression models were first run including only the chemical and creatinine (natural log-transformed, mg/dl) concentrations and, subsequently, to adjust for *a priori* specified covariates in light of the dearth of information about these chemicals and male fecundity: age (years), BMI (kg/m^2), active smoking status (serum cotinine >40.35 ng/ml) (33), creatinine (log-transformed, left continuous), season (spring, summer, winter, fall), and research site (Michigan/Texas). Our rationale for modeling creatinine continuously was to account for the inter-individual variation in concentration to more closely reflect men's urinary dilution while preserving statistical power. Selection was based upon factors associated with distributions of other non-persistent chemicals, observed associations with exposures and to account for any residual confounding by site. Separate models were run for each chemical and semen endpoint. In light of this exploratory analysis, we did not adjust for multiple comparisons. All analyses were performed in SAS version 9.3.

Results

As reflected in Table 1, the cohort comprised mostly non-Hispanic White (81%), college educated (99%) men who had health insurance (92%), and who had not previously fathered a pregnancy (53%). With regard to lifestyle, most men reported some weekly alcohol consumption (52%), though fewer reported regular exercise (42%) or actively smoking cigarettes (14%). Among men providing semen samples, the average abstinence period was 4 days and most men reported no spillage (89%). Eighty-eight percent (n=413) of men had

both urine and semen samples available for analysis and comprise the final sample for analysis, none of which were found to be azoospermic.

Geometric means and accompanying 95% CIs are provided in Table 2 and reflect a range of exposures with the highest detectable urinary concentrations for BP-1 followed by BP-3, 4OH-BP, BP-8, and BP-2. Of note is the observation that 28.1% of the concentrations for BP-2 was <LOD, and 27.4% for BP-8. Correlation coefficients for the 5 BP-type UV filters were low, ranging from −0.03 (BP-8 and BP-2) to 0.46 (BP-1 and BP-8). However, BP-3 and BP-1 were highly correlated (0.92, p <0.0001), consistent with BP-1 being considered a metabolite of BP-3 (data not shown).

Two of the five BP-filters were observed to be significantly associated with one or more semen endpoints in the adjusted analyses (Table 3), with specific associations observed for each of the two chemicals. BP-2 was associated with five semen endpoints including diminished sperm concentration (β=−0.74; 95% CI −1.41, −0.08), a lower percentage of straight (β=−4.57; 95% CI −8.95, −0.18) and linear moving sperm (β=−3.15; 95% CI −6.01, −0.30), and an increased number of immature sperm (β=0.38; 95% CI 0.15, 0.62), but a decreased percentage of other tail abnormalities (β=−0.16; 95% CI −0.31, −0.01). BP-8 was associated with two sperm characteristics including a decreased percentage of hypo-osmotic swollen sperm (β=−2.57; 95% CI −4.86, −0.29) and an increased percentage of acrosome area (β=1.14; 95% CI 0.01, 2.26). No significant associations were observed for either BP-1, BP-3 or 4OH-BP.

Discussion

We found some evidence suggesting that two of five measured BP-type UV filters were associated with one or more semen endpoints, with some estimates suggestive of reductions in select semen quality endpoints. Specifically, men above the 75th percentile for BP-2 and BP-8 had more changes in semen quality in comparison to men below this cut point. BP-2 was significantly associated with five semen quality endpoints, viz., decreased sperm concentration, decreased percentage of straight and linear movement, increased number of immature sperm, and a decreased percentage of other tail anomalies. BP-8 was associated with negatively associated with hypo-osmotic swelling, but positively associated with acrosome area. Of note is the absence of any significant associations for BP-1, BP-3 or 4OH-BP. Collectively, these findings suggest that the metabolic derivatives (BP-2 and BP-8) may be more relevant for semen quality than their parent compound, BP-3. The extent to which these observations may reflect higher reported estrogenic activity for the derivative BP-2 relative to its parent compound, BP-3 (3, 34) remains to be established in light of more signals observed for the former versus latter compound. Still, the estrogenic potencies of BP-3 are 1,000 – 100,000 times lower than 17-β-estradiol, yet higher than other xenoestrogens such as BPA (35), and the potencies for BP-2 await further research. Another mode of action may be via anti-androgenic pathways (14, 15). Of note, 4OH-BP is a pharmaceutical intermediate of clomiphene citrate, a selective estrogen receptor modulator, underscoring its hormonal properties (36).

In light of this being the first investigation of BP-type UV filters and semen quality, we are unable to more fully interpret our findings in the context of previous literature and wish to stress the preliminary nature of these findings and the need for cautious interpretation of the findings. We are aware of one previous paper reporting that BP-3 can be detected and quantified in semen (37). In our previous paper focusing on these same five BP-type UV filters as measured in both partners of the couples participating in the LIFE Study, we found that male partners' BP-2 concentrations were associated with a significant 31% reduction in couple fecundity resulting in a longer time-to-pregnancy even after adjusting for the female partners concentrations (18). While speculative, it remains possible that BP-2 may account for the longer observed time-to-pregnancy, perhaps through subtle alterations in semen endpoints. Further investigation of these findings is needed. In light of our exploratory analytic plan consistent with this work representing one of the earliest undertaking for this class of environmental chemicals and male fecundity as measured by semen quality, we refrain from further interpretation of the point estimates (i.e., beta coefficients) and emphasize that they are not directly comparable, given the number of independent models run. Rather, we summarize the results as supporting the need for additional research to corroborate (or not) these early findings. Our findings underscore the need for research beyond BP-3 to include other chemicals in this class, including its presumed derivatives to understand any potential implications for human fecundity.

There is a small body of animal evidence focusing on BP-type UV filters and male reproduction. For example, BP-2 has been associated with hypospadias in mice (38). The estrogenic effects of BP-2 have been demonstrated in fathead minnows where dose-dependent relationships were observed with gonad histology (testes had fewer spermatocytes), secondary sex characteristics and reproduction (39). In zebrafish, low levels of BP-3 concentrations inhibited steroidogenesis and affected hormonal milieu at different developmental stages (40). The relevancy of these findings for human populations awaits future investigation.

In light of this study representing an initial attempt to assess BP-type UV filters and semen quality, as globally measured by various endpoints, cautious interpretation of the findings is needed. Most notably, our research relied upon a single preconception measurement of BP-type UV filters. The degree to which this timing is relevant for the period of spermatogenesis remains to be established. Other research focusing on non-persistent chemicals such as BPA and phthalates and semen quality has also relied upon a single spot urine, which has prompted investigators to assess the reliability of a single measurement. We are aware of three publications reporting intra-class correlations (ICCs) for BP-3. Among 105 pregnant women in Puerto Rico, the ICC was 0.62 (41). Higher ICCs ranging from 0.80–0.92 were reported for a sample of 33 young Danish men (42) and in a sample of four Flemish couples (43).

Our modeling approach for this exploratory analysis was designed to differentiate men with higher versus lower concentrations of UV filters in the context of *a priori* specified covariates. As such, our findings need to be interpreted with these intentions recognizing that we cannot eliminate potential residual confounding and that our findings may be to model specification. Our findings are based on a dichotomized exposure at the 75th

percentile for each chemical, which mitigates the influence of non-linear relations between exposures and semen endpoints. Further work including various modeling options based upon reported exposure distributions will help to delineate potential associations meaningful for human fecundity. While our models appropriately accommodated repeated semen samples per male, we cannot rule out chance findings as we did not control for multiple comparisons in light of our efforts to fully explore the BP-type UV filters and semen quality beyond the semen endpoints typically reported.

Other important limitations include the absence of a urologic examination that might have identified factors associated with semen quality. However, the extent to which such pathology might also be associated with UV-filters is unknown. Use of a 24-hour semen analysis is in keeping the population-based sampling framework used in the LIFE Study and reliance on next day analysis, which has been used in previous studies focusing on environmental chemicals and semen quality (44). Previous authors have compared at-home with clinic-based semen collection with regard to a range of semen endpoints save for DNA fragmentation, and reported no clinically significant effect of at-home collection on semen quality endpoints including morphology (45). In fact, some authors report that at-home collection may be associated with higher quality semen endpoints than clinic-based collection (46, 47). Still we recognize that our semen analysis is not interchangeable with a clinical diagnostic analysis. We also recognize that motility is sensitive to time underscoring the need for cautious interpretation of the motility findings. Also, there are some data suggesting that sperm DNA fragmentation increases over time (48, 49), though it is unlikely to be systematically associated with male partners' pre-conception concentrations of urinary BP-type UV filters. Finally, careful interpretation of our findings is needed given that most of the signals were for the two BP-type UV filters with the highest percentage of measurements <LOD. Still, we know of no data to support a systematic difference in urine concentrations above or below the LOD, as the analytic laboratory was blinded to study participants' semen quality.

In sum, we observed that two of five measured BP-type UV filters were associated with changes in semen endpoints including sperm concentration, sperm viability, motility, sperm head, and morphology. Whether such changes are sufficient to affect couple fecundity as measured by the time needed to achieve pregnancy or other couple dependent fertility outcomes remain to be established, as do underlying mechanisms.

Acknowledgments

References

1. Vested A, Ramlau-Hansen CH, Olsen SF, Bonde JP, Kristensen SL, Halldorsson TI, et al. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. Environ Health Perspec. 2013; 121:453–8.

2. McAuliffe ME, Williams PL, Korrick SA, Altshul LM, Perry MJ. Environmental exposures polychlorinated biphenyls and p,p′-DDE and sperm sex-chromosome disomy. Environ Health Perspect. 2012; 120:535–40. [PubMed: 22189045]

3. Mumford SL, Kim S, Chen Z, Gore-Langton RE, Boyd Barr D, Buck Louis GM. Persistent organic pollutants and semen quality: The LIFE Study. Chemosphere. 2014 Nov 28. S0045-6535(14)01278-8. doi:10.1016.

4. Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen Z, et al. Phthalate exposure and human semen parameters. Epidemiology. 2003; 14:269–77. [PubMed: 12859026]

5. Knez J, Kranvogl R, Breznik BP, Von ina E, Vlaisavljevi V. Are urinary bisphenol A levels in men related to semen quality and embryo development after medically assisted reproduction? Fertil Steril. 2014; 101:215–21.e5. [PubMed: 24182411]

6. Joensen UN, Frederiksen H, Blomberg Jensen M, Lauritsen MP, Olesen IA, Lassen TH, et al. Phthalate excretion pattern and testicular function: a study of 881 healthy Danish Men. Environ Health Perspect. 2012; 120:1397–403. [PubMed: 22832070]

7. Goldstone AE, Chen Z, Perry MJ, Kannan K, Buck Louis GM. Urinary bisphenol A and semen quality, the LIFE Study. Reprod Toxicol. 2014; 11:51C, 7–13.

8. Calafat AM, Wong LY, Ye X, Reidy JA, Needham LL. Concentrations of the sunscreen agent benzophenone-3 in residents of the United States: National Health and Nutrition Examination Survey, 2003–2004. Environ Health Perspect. 2008; 116:893–7. [PubMed: 18629311]

9. Wang L, Kannan K. Characteristic profiles of benzophenone-3 and its derivatives in urine of children and adults from the United States and China. Environ Sci Technol. 2013; 47:12532–8. [PubMed: 24073792]

10. Suzuki T, Kitamura S, Khota R, Sugihara K, Fujimoto N, Ohta S. Estrogenic and antiandrogenic activities of 17 benzophenone derivatives used as UV stabilizers and sunscreens. Toxicol Appl Pharmacol. 2005; 203:9–17. [PubMed: 15694459]

11. Muncke J. Endocrine disrupting chemicals and other substances of concern in food contact materials: an updated review of exposure, effect and risk assessment. J Steroid Biochem Mol Biol. 2011; 127:118–27. [PubMed: 21073950]

12. Jiang R, Roberts MS, Collins DM, Benson HAE. Absorption of sunscreens across human skin: An evaluation of commercial products for children and adults. Br J Clin Pharmacol. 1999; 48:635–7. [PubMed: 10583038]

13. Janjua NR, Mogensen B, Andersson AM, Petersen JH, Henriksen M, Skakkebaek NE, et al. Systemic absorption of the sunscreens benzophenone-3, octyl-methoxycinnamete, and 3-(4-methyl-benzylidene) camphor after whole-body topical application and reproductive hormone levels in humans. J Invest Dermatol. 2004; 123:57–61. [PubMed: 15191542]

14. Ma RS, Cotton B, Lichtensteiger W, Shlumpf M. UV filters with antagonistic action at androgen receptors in the MDA-kb2 cell transcriptional-activity assay. Toxicol Sci. 2003; 74:43–50. [PubMed: 12730620]

15. Schreurs RHMM, Sonneveld E, Jansen JHJ, Seinen W, van der Burg B. Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays. Toxicol Sci. 2005; 83:264–72. [PubMed: 15537743]

16. Kawamura Y, Mutsuga M, Kato T, Iida M, Tanamoto K. Estrogenic and anti-androgenic activities of benzophenones in human estrogen and androgen receptor mediated mammalian reporter gene assays. J Health Sci. 2005; 51:48–54.

17. Kunisue T, Chen Z, Buck Louis GM, Sundaram R, Hediger ML, Sun L, et al. Urinary concentrations of benzophenone-type UV filters in U.S. women and their association with endometriosis. Environ Sci Technol. 2014; 46:4624–32. [PubMed: 22417702]

18. Buck Louis GM, Kannan K, Sapra KJ, Maisog J, Sundaram R. Urinary concentrations of benzophenone-type UV filters and couple fecundity. Am J Epidemiol. 2014; 180:1168–75. [PubMed: 25395025]

19. Buck Louis GM, Schisterman EF, Sweeney AM, Wilcosky TC, Gore-Langton RE, Lynch CD, et al. Designing prospective cohort studies for assessing reproductive and developmental toxicity during sensitive windows of human reproduction and development – the LIFE Study. Paediatr Perinatal Epidemio. 2011; 25:413–24.

20. Okereke CS, Abdel-Rhaman MS, Friedman MA. Disposition of benzophenone-3 after dermal administration in male rats. Toxicol Lett. 1994; 73:113–22. [PubMed: 8048080]

21. Zhang T, Sun H, Qin X, Wu Q, Zhang Y, Ma J, et al. Benzophenone-type UV filters in urine and blood from children, adults, and pregnant women in China: Partitioning between blood and urine as well as maternal and fetal cord blood. Sci Total Environ. 2013; 461–462:49–55.

22. Kim S, Choi K. Occurrences, toxicities, and ecological risk of benzophenone-3, a common component of organic sunscreen products: A mini-review. Environ International. 2014; 70:143–57.

23. Kunisue T, Wu Q, Tanabe S, Aldous KM, Kannan K. Analysis of five benzophenone-type UV filters in human urine by liquid chromatography-tandem mass spectrometry. Anal Methods. 2010; 2:707–13.

24. Richardson DB, Ciampi A. Effects of exposure measurement error when an exposure variable is constrained by a lower limit. Am J Epidemiol. 2003; 157:355–63. [PubMed: 12578806]

25. Schisterman EF, Vexler A, Whitcomb BW, Liu A. The limitations due to exposure detection limits for regression models. Am J Epidemiol. 2006; 163:374–83. [PubMed: 16394206]

26. Bernert JT Jr, Turner WE, Pirkle JL, Sosnoff CS, Akins JR, Waldrep MK, et al. Development and validation of sensitive method for determination of serum cotinine in smokers and nonsmokers by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Clin Chem. 1997; 43:2281–91. [PubMed: 9439445]

27. Buck Louis GM, Sundaram R, Schisterman EF, Sweeney A, Lynch CD, Kim S, et al. Semen quality and time-to-pregnancy, the LIFE Study. Fertil Steril. 2014; 101:453–62. [PubMed: 24239161]

28. Evenson DP, Larson KL, Jost LK. Sperm chromatin structure assay: Its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques. J Androl. 2002; 23:25–43. [PubMed: 11780920]

29. World Health Organization. Laboratory manual for the examination of human semen and semen-cervical mucus interaction. 3. Cambridge: Cambridge University Press; 1992.

30. Rothmann, SA.; Bort, A-M.; Quigley, J.; Pillow, R. Sperm morphology classification: a rational method for schemes adopted by the World Health Organization. In: Carrell, DT.; Aston, KI., editors. Spermatogenesis: Methods and Protocols. New York: Humana Press; 2013. p. 27-38.

31. Handelsman DJ. Optimal power transformations for analysis of sperm concentration and other semen variables. J Andrology. 2002; 23:629–34.

32. Buck Louis GM, Chen Z, Schisterman EF, Kim S, Sweeney AM, Sundaram R, et al. Perflurochemicals and Human Semen Quality, the LIFE Study. Environmental Health Perspectives. 2015; 123(1):57–63. [PubMed: 25127343]

33. Jeemon P, Agarwal S, Ramakrishnan L, Gupta R, Snehi U, Chaturvedi V, et al. Validation of self-reported smoking status by measuring serum cotinine levels: An Indian perspective. Nat Med J India. 2010; 23:134–36.

34. Morohoshi K, Yamamoto H, Kamata R, Shiraishi F, Koda T, Morita M. Estrogenic activity of 37 components of commercial sunscreen lotions evaluated by in vitro assays. Toxicol In Vitro. 2005; 19:457–69. [PubMed: 15826804]

35. Kawamura Y, Ogawa Y, Nishimura T, Kikuchi Y, Nishkawa J-I, Nishihara T, et al. Estrogenic activities of UV stabilizers used in food contact plastics and benzophenone derivatives tested by the yeast two-hybrid assay. J Health Sci. 2003; 49:205–12.

36. Grinenko GS, Dolginova EM, Kadatskii GM, Liberman SS. Clomiphene citrate – An antiestrogenic preparation with a nonsteroid structure. Pharm Chem J. 1989; 23:75–82.

37. León Z, Chisvert A, Tarazona I, Salvador A. Solid-phase extraction liquid chromatography-tandem mass spectrometry analytical method for the determination of 2-hydroxy-4-methoxybenzophenone and its metabolites in both human urine and semen. Anal Bioanal Chem. 2010; 398:831–43. [PubMed: 20625888]

38. Hsieh MH, Grantham EC, Liu B, Bacapagal R, Willingham E, Baskin LS. In utero exposure to benzophenone-2 causes hypospadias through an estrogen receptor dependent mechanism. J Urol. 2007; 178:1637–42. [PubMed: 17707034]

39. Weisbrod CJ, Kunz PY, Zenker AK, Fent K. Effects of UV filter benzophenone-2 on reproduction in fish. Toxicol Appl Pharmacol. 2007; 225:2555–66.

40. Blüthgen N, Zucchi S, Fent K. Effects of the UV filter benzophenone-3 (oxybenzone) at low concentrations in zebrafish (*Danio rerio)*. Toxicol Appl Pharmacol. 2012; 263:184–94. [PubMed: 22721600]

41. Meeker JD, Cantonwine DE, Rivera-Gonzalez LO, Ferguson KK, Mukherjee B, Calafat AM, et al. Distribution, variability, and predictors of urinary concentrations of phenols and parabens among pregnant women in Puerto Rico. Environ Sci Technol. 2013; 47:3439–47. [PubMed: 23469879]

42. Lassen TH, Frederiksen H, Jensen TK, Petersen JH, Main KM, Skakkebæk NE, et al. Temporal variability in urinary excretion of bisphenol A and seven other phenols in spot, morning, and 24-h urine samples. Environ Res. 2013; 126:164–70. [PubMed: 23932849]

43. Koch HM, Aylward LL, Hays SM, Smolders R, Moos RK, Cocker J, et al. Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 2: Personal care product ingredients. Toxicol Letters. 2014 (Available online ahead of print on June 20, 2014). 10.1016/j.toxlet.2014.06.023

44. Luben TJ, Olshan AF, Herring AH, Jeffay S, Strader L, Buus RM, Chan RL, Savitz DA, Singer PC, Weinberg HS, Perreault SD. Environ Health Perspect. 2007; 115(8):1169–76. [PubMed: 17687443]

45. Licht RS, Handel L, Sigman M. Site of semen collection and its effect on semen analysis parameters. Fertil Steril. 2008; 89(2):395–397. [PubMed: 17482174]

46. Elzanaty S, Malm J. Comparison of semen parameters in samples collected by masturbation at a clinic and at home. Fertil Steril. 2008; 89(6):1718–22. [PubMed: 17658521]

47. Wang W, Zhong ZM, Su N, Peng YY, Huang TT. Location of semen collection and semen quality: clinic-collected versus home-collected samples. Zhonghua Nan Ke Xue. 2014; 20(11):995–8. [PubMed: 25577834]

48. Gosálvez J, Cortés-Gutierez E, López-Fernández C, Fernández JL, Caballero P, Nuñez R. Sperm deoxyribonucleic acid fragmentation dynamics in fertile donors. Fertil Steril. 2009 Jul; 92(1):170–3. [PubMed: 18692792]

49. Gosálvez J, Núñez R, Fernández JL, López-Fernández C, Caballero P. Dynamics of sperm DNA damage in fresh versus frozen-thawed and gradient processed ejaculates in human donors. Andrologia. 2011 Dec; 43(6):373–7. [PubMed: 21919930]

Table 1

Description of male partners, LIFE Study (n=413).

Characteristic	n	%
Age (years):		
24	14	3
25–29	128	31
30–34	158	38
35–39	83	20
40	30	7
Mean (±SD)	31.8 (4.8)	
Self identified race/ethnicity:		
White, non-Hispanic	334	81
Black, non-Hispanic	18	4
Hispanic	33	8
Other	28	7
Education:		
High school education	3	1
Some college/college graduate	30	7
Graduate/professional school	378	92
Health insurance:		
No	35	8
Yes	378	92
Previously fathered a pregnancy:		
No	219	53
Yes	193	47
Cigarette smoker at enrollment:		
No	354	86
Yes	59	14
Mean (±SD) serum cotinine (ng/ml)[*]	54.5 (135.7)	
Drinking alcoholic beverages at enrollment:		
No	58	14
Yes, sporadic (3 drink/month)	130	31
Yes, regular (6 drink/week)	213	52
Yes, daily	12	3
Body mass index (kg/m^2):		
Thin (<25.0)	69	17
Normal (25.0–29.9)	169	43
Overweight (30.0–34.9)	105	27
Obese (35.0)	54	14

Characteristic	n	%
Regular exercise:		
No	239	58
Yes	174	42
Abstinence (# days):		
1	1	<1
2	165	41
3	236	59
Mean (±SD)	4.03 (5.0)	
Reported spillage of semen:		
No	359	89
Yes	43	11
Geometric mean (95% CI) creatinine (ug/g)	113.96 (105.77, 122.8)	

NOTE: Restricted to male partners with available urine and semen for analysis.

[*] p 0.01 with BP-1 and BP-3.

SD, standard deviation.

Table 2

Distribution of benzophenone-type ultra violet light filter concentrations by creatinine adjustment status.

UV filters	Unadjusted (ng/ml)			Creatinine Adjusted (ug/g)		
	% <LOD	Geometric Mean	95% Confidence Interval	Geometric Mean	95% Confidence Interval	
BP-1	1.21	1.89	1.54, 2.31	1.79	1.44, 2.22	
BP-2	28.09	0.05	0.04, 0.06	0.05	0.04, 0.06	
BP-3	1.69	4.42	3.63, 5.38	4.13	3.35, 5.09	
BP-8	27.36	0.11	0.09, 0.15	0.12	0.09, 0.16	
4OH-BP	4.36	0.14	0.13, 0.16	0.13	0.11, 0.14	

NOTE: All data were rounded to two decimal places.

UV, ultra violet; LOD, limit of detection; BP-1, 2,4-dihydroxybenzophenone; BP-2, 2,2′,4,4′-tetrahydroxybenzophenone; BP-3, 2-hydroxy-4-methoxybenzophenone; BP-8, 2,2′-dihydroxy-4-methoxybenzophenone; 4OH-BP, 4-hydroxybenzophenone.

Table 3

Benzophenone-type ultra violet filter concentrations (dichotomized at the 75th percentile) and semen quality endpoints - adjusted linear mixed modeling results.

Semen Quality Endpoint	BP-1 β	BP-1 95% CI	BP-2 β	BP-2 95% CI	BP-3 β	BP-3 95% CI	BP-8 β	BP-8 95% CI	4OH-BP β	4OH-BP 95% CI
General Characteristics										
Volume (mL)	0.13	−0.04, 0.29	0.04	−0.13, 0.22	0.12	−0.04, 0.28	0.09	−0.08, 0.26	0.04	−0.13, 0.21
Sperm concentration (×10^6/mL)	−0.05	−0.69, 0.59	**−0.74**	**−1.41, −0.08**	0.11	−0.53, 0.74	−0.03	−0.68, 0.61	−0.49	−1.16, 0.18
Total sperm count (x10^6/ejaculate)	0.41	−0.55, 1.36	−0.91	−1.91, 0.09	0.59	−0.36, 1.55	0.22	−0.75, 1.18	−0.40	−1.40, 0.61
Hypo-osmotic swollen (%)	0.22	−2.05, 2.50	−1.75	−4.14, 0.63	−0.13	−2.40, 2.14	**−2.57**	**−4.86, −0.29**	−0.34	−2.73, 2.05
Straw distance (mm)	0.01	−0.13, 0.15	0.02	−0.13, 0.17	0.00	−0.13, 0.14	−0.06	−0.20, 0.08	−0.01	−0.15, 0.14
Sperm Motility (24 hour)										
Average path velocity (μm/sec)	0.72	−2.05, 3.49	−0.62	−3.53, 2.30	0.33	−2.44, 3.10	−0.63	−3.43, 2.16	1.29	−1.63, 4.20
Straight line velocity (μm/sec)	0.12	−2.15, 2.40	−0.71	−3.10, 1.69	−0.37	−2.64, 1.91	−1.00	−3.30, 1.30	0.78	−1.61, 3.18
Curvilinear velocity (μm/sec)	1.92	−2.91, 6.75	−0.27	−5.35, 4.80	1.10	−3.73, 5.93	−1.18	−6.06, 3.70	3.83	−1.24, 8.90
Amplitude head displacement (μm)	0.01	−0.29, 0.32	0.03	−0.29, 0.35	0.04	1.29, −1.63	−0.02	−0.33, 0.29	0.29	−0.03, 0.61
Beat cross frequency (Hz)	1.01	−0.52, 2.54	−0.47	−2.08, 1.14	0.67	−0.86, 2.20	−0.98	−2.52, 0.56	0.50	−1.11, 2.11
Straightness (%)	0.30	−3.89, 4.50	**−4.57**	**−8.95, −0.18**	−0.19	1.29, −1.63	−3.51	−7.72, 0.71	−0.89	−5.29, 3.52
Linearity (%)	0.05	−2.68, 2.78	**−3.15**	**−6.01, −0.30**	−0.19	−2.92, 2.54	−2.25	−4.99, 0.49	−1.56	−4.42, 1.30
Percent motility (%)	−0.23	−0.87, 0.40	−0.31	−0.98, 0.36	−0.36	−1.00, 0.27	−0.37	−1.01, 0.27	−0.30	−0.97, 0.37
Sperm Head Measurements										
Length (μm)	−0.01	−0.02, 0.01	0.01	−0.01, 0.02	−0.01	−0.02, 0.00	0.00	−0.01, 0.02	0.00	−0.02, 0.01
Area (μm^2)	−0.12	−0.32, 0.08	−0.07	−0.28, 0.14	−0.13	−0.33, 0.07	−0.04	−0.24, 0.16	−0.06	−0.27, 0.15
Width (μm)	−0.02	−0.06, 0.02	−0.04	−0.08, 0.00	−0.01	−0.05, 0.03	−0.03	−0.08, 0.01	0.00	−0.05, 0.04
Elongation factor (%)	−0.02	−1.27, 1.23	−1.29	−2.60, 0.01	0.41	−0.84, 1.66	−1.13	−2.39, 0.14	0.00	−1.32, 1.32
Perimeter (μm)	−0.07	−0.19, 0.05	0.02	−0.10, 0.15	−0.08	−0.20, 0.03	0.01	−0.10, 0.13	−0.04	−0.16, 0.08
Acrosome area of head (%)	0.59	−0.53, 1.70	−0.82	−1.99, 0.35	0.88	−0.24, 1.99	**1.14**	**0.01, 2.26**	−0.01	−1.19, 1.17
Morphology										
Strict criteria (%)[a]	0.59	−0.47, 1.64	−0.85	−1.99, 0.30	0.40	−0.66, 1.45	−0.08	−1.16, 1.00	0.72	−0.41, 1.86

Semen Quality Endpoint	BP-1		BP-2		BP-3		BP-8		4OH-BP	
	β	95% CI	β	95% CI	β	95% CI	β	95% CI	β	95% CI
Traditional normal (%)[a]	1.92	−1.18, 5.02	−2.64	−6.00, 0.71	1.46	−1.63, 4.56	−0.14	−3.31, 3.03	1.35	−1.98, 4.68
Amorphous (%)	−0.13	−0.37, 0.12	0.23	−0.04, 0.50	−0.15	−0.40, 0.09	−0.06	−0.32, 0.19	0.02	−0.25, 0.28
Round (%)	−0.02	−0.15, 0.11	0.09	−0.05, 0.23	0.02	−0.11, 0.15	−0.01	−0.15, 0.12	−0.04	−0.18, 0.10
Pyriform (%)	0.03	−0.17, 0.22	0.11	−0.10, 0.32	−0.02	−0.22, 0.17	0.15	−0.05, 0.35	−0.01	−0.23, 0.20
Bicephalic (%)	−0.04	−0.17, 0.10	0.12	−0.03, 0.27	−0.04	−0.17, 0.10	0.00	−0.14, 0.13	−0.03	−0.18, 0.11
Taper (%)	−0.06	−0.22, 0.11	0.09	−0.09, 0.26	−0.09	−0.25, 0.07	0.05	−0.11, 0.22	−0.01	−0.18, 0.17
Megalo head (%)	0.02	−0.10, 0.14	0.11	−0.02, 0.24	−0.02	−0.14, 0.10	0.03	−0.09, 0.15	0.07	−0.06, 0.19
Micro head (%)	−0.02	−0.13, 0.09	0.00	−0.12, 0.12	−0.03	−0.14, 0.08	0.05	−0.06, 0.17	−0.04	−0.16, 0.08
Neck/mid-piece abnormalities (%)	−0.05	−0.14, 0.04	0.05	−0.04, 0.15	−0.02	−0.11, 0.06	0.00	−0.09, 0.09	−0.05	−0.15, 0.05
Coiled tail (%)	0.05	−0.06, 0.15	−0.01	−0.12, 0.11	0.02	−0.09, 0.13	−0.01	−0.12, 0.10	−0.02	−0.13, 0.10
Other tail abnormalities (%)	−0.11	−0.24, 0.03	**−0.16**	**−0.31, −0.01**	−0.08	−0.22, 0.06	−0.03	−0.17, 0.11	−0.07	−0.21, 0.08
Cytoplasmic droplet (%)	0.09	−0.17, 0.35	0.09	−0.19, 0.37	0.07	−0.19, 0.33	−0.03	−0.29, 0.24	0.10	−0.18, 0.38
Immature sperm (#)	0.08	−0.14, 0.30	**0.38**	**0.15, 0.62**	0.05	−0.17, 0.27	0.01	−0.21, 0.24	0.16	−0.08, 0.40
Sperm Chromatin Stability Assay										
DNA fragmentation index (%)	−0.02	−0.15, 0.11	−0.01	−0.14, 0.13	0.00	−0.13, 0.12	0.09	−0.04, 0.22	−0.04	−0.18, 0.09
High DNA stainability (%)	−0.08	−0.21, 0.06	0.13	−0.01, 0.27	−0.09	−0.22, 0.04	−0.09	−0.23, 0.04	0.01	−0.13, 0.15

NOTE: Models include each UV-filter dichotomized at the 75th percentile, creatinine (log-transformed), age, body mass index, active smoking (serum cotinine >43.5 ng/ml), season of enrollment (winter, spring, summer, fall), and research site. Various semen endpoints were transformed as stated in methods. Significant findings are in boldface.

[a]Traditional and strict criteria – differentials were conducted using the traditional morphology.

CI, confidence interval; BP-1, 2,4-dihydroxybenzophenone; BP-2, 2,2′,4,4′-tetrahydroxybenzophenone; BP-3, 2-hydroxy-4-methoxybenzophenone; BP-8, 2,2′-dihydroxy-4-methoxybenzophenone; 4OH-BP, 4-hydroxybenzophenone.